Mark Buyyounouski, MD, MS, a radiation oncologist at Fox Chase Cancer Center, has developed a tool that can determine a patient's risk of dying from prostate cancer after he has received radiation treatment, Medical News Today reported.
The device, called a nomogram, works by measuring the levels of PSA in the patient's blood. Researchers at Fox Chase recently found that they could accurately predict a patient's risk of dying from prostate cancer by measuring the time between the last radiation treatment and biochemical failure.
Nomograms currently exist to help patients and physicians decide on a course of treatment, but this is the first kind to determine a patient's death risk after receiving treatment.
Related Articles on Medical Devices:
GE's New MRI Machine Gets FDA Approval
FDA Approves Gel to Temporarily Stop Blood Flow
FDA Clears Siemens' Mobilett Mira Mobile Digital X-Ray System
The device, called a nomogram, works by measuring the levels of PSA in the patient's blood. Researchers at Fox Chase recently found that they could accurately predict a patient's risk of dying from prostate cancer by measuring the time between the last radiation treatment and biochemical failure.
Nomograms currently exist to help patients and physicians decide on a course of treatment, but this is the first kind to determine a patient's death risk after receiving treatment.
Related Articles on Medical Devices:
GE's New MRI Machine Gets FDA Approval
FDA Approves Gel to Temporarily Stop Blood Flow
FDA Clears Siemens' Mobilett Mira Mobile Digital X-Ray System